Novel variants of muscle calpain 3 identified in human melanoma cells: Cisplatin-induced changes in vitro and differential expression in melanocytic lesions

Carcinogenesis

Volumn 30, Issue 6, 2009, Pages 960-967

  Moretti, D ^a   Del Bello, B ^a   Cosci, E ^a   Biagioli, M ^a   Miracco, C ^a   Maellaro, E ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN 3; CALPEPTIN; CISPLATIN; HUMAN MELANOMA P78 PROTEIN; HUMAN MELANOMA P84 PROTEIN; ISOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; EXON; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENETIC STABILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; NEVUS; NUCLEOLUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RNA SPLICING;

ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOPSY; CALPAIN; CELL LINE, TUMOR; CELL NUCLEOLUS; CISPLATIN; CYTOPLASM; DIPEPTIDES; DYSPLASTIC NEVUS SYNDROME; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MUSCLE PROTEINS; NEOPLASM METASTASIS; NEVUS; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 66749173427     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp098     Document Type: Article

References (34)

1. Goll,D.E. et al. (2003) The calpain system. Physiol. Rev., 83, 731-801.
2. Suzuki,K. et al. (2004) Structure, activation and biology of calpain. Diabetes, 53, S12-S18.
3. Sorimachi,H. et al. (1997) Structure and physiological function of calpains. Biochem. J., 328, 721-732.
4. Sato,K. et al. (2001) Calpain function in the modulation of signal transduction molecules. Biol. Chem., 382, 743-751.
5. Neumar,R.W. et al. (2003) Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J. Biol. Chem., 278, 14162-14167.
6. Del Bello,B. et al. (2007) Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: A major role of calpain inhibition in cell death protection and p53 status. Oncogene, 26, 2717-2726.
7. Busquet,S. et al. (2000) Calpain-3 gene expression is decreased during experimental cancer cachexia. Biochim. Biophys. Acta, 1475, 5-9.
8. Branca,D. (2004) Calpain-related diseases. Biochem. Biophys. Res. Commun., 322, 1098-1104.
9. Baghdiguian,S. et al. (1999) Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkBα/NF-kB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med., 5 503-511.
10. Sorimachi,H. et al. (1989) Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and μ-types. Specific expression of the mRNA in skeletal muscle. J. Biol. Chem., 264 20106-20111.
11. De Tullio,R. et al. (2003) Characterization of a new p94-like calpain form in human lymphocytes. Biochem. J., 375, 689-696.
12. Kawabata,Y. et al. (2003) Newly identified exons encoding novel variants of p94/calpain 3 are expressed ubiquitously and overlap the α-glucosidase C gene. FEBS Lett., 555, 623-630.
13. Weeraratna,A. et al. (2004) Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 23, 2264-2274.
14. Gollob,J.A. et al. (2005) Gene expression changes and signalling events associated with the direct antimelanoma effect of IFN-γ. Cancer Res., 65, 8869-8877.
15. Del Bello,B. et al. (2004) Role of caspases-3 and -7 in Apaf-1 proteolytic cleavage and degradation events during cisplatin-induced apoptosis in melanoma cells. Exp. Cell Res., 293, 302-310.
16. Kyo,S. et al. (2003) Significance of immunological detection of human telomerase reverse transcriptase: Re-evaluation of expression and localization of human telomerase reverse transcriptase. Am. J. Pathol., 163, 859-867.
17. Okun,M.R. et al. (2003) What criteria reliably distinguish melanoma from benign melanocytic lesions? Histopathology, 37 464-466.
18. Miracco,C. et al. (2006) Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Int. J. Oncol., 28, 345-352.
19. Kinbara,K. et al. (1998) Purification of native p94, a muscle-specific calpain, and characterization of its autolysis. Biochem. J., 335, 589-596.
20. Ono,Y. et al. (2008) The importance of conserved amino acid residues in p94 protease sub-domain IIb and the IS2 region for constitutive autolysis. FEBS Lett., 582, 691-698.
21. Sorimachi,H. et al. (1993) Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J. Biol. Chem., 268, 10593-10605.
22. Garzia Diaz,B. et al. (2004) Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide. J. Biol. Chem., 26, 27656-27666.
23. Herasse,M. et al. (1999) Expression and functional characteristics of calpain 3 isoforms generated through tissue-specific transcriptional and post-transcriptional events. Mol. Cell. Biol., 19, 4047-4055.
24. Hayashi,C. et al. (2008) Multiple molecular interactions implicate the connectin/titin N2A region as a modulating scaffold for p94/calpain 3 activity in skeletal muscle. J. Biol. Chem., 283, 14801-14814.
25. Soengas,M.S. et al. (2003) Apoptosis and melanoma chemoresistance. Oncogene, 22, 3138-3151.
26. Hersey,P. et al. (2006) Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. Int. Rev. Cytol., 251, 131-158.
27. Ono,Y. et al. (2004) Possible regulation of the conventional calpain system by skeletal muscle-specific calpain, p94/calpain 3. J. Biol. Chem., 279, 2761-2771.
28. Richard,I. et al. (1995) Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell, 81, 27-40.
29. Taveau,M. et al. (2003) Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol. Cell. Biol., 23, 9127-9135.
30. Kramerova,I. et al. (2006) Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation. Mol. Cell. Biol., 26, 8437-8447.
31. Ono,Y. et al. (2007) Comprehensive survey of p94/calpain 3 substrates by comparative proteomics - possible regulation of protein synthesis by p94. Biotechnol. J., 2, 565-576.
32. Maggi,L.B. et al. (2005) Nucleolar adaptation in human cancer. Cancer Invest., 23, 599-608.
33. Weber,J.D. et al. (1999) Nucleolar ARF sequesters Mdm2 and activates p53. Nat. Cell Biol., 1, 20-26.
34. Larue,L. et al. (2006) The WNT/Beta-catenin pathway in melanoma. Front. Biosci., 11, 733-742.